Phase III studies in the first-line NSCLC setting in populations unselected for EGFR mutation have shown varying degrees of clinical efficacy for EGFR-targeted agent–chemotherapy combinations versus chemotherapy alone [15‒17]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.